Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 15/20 | 0.66 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8473641 | 0.87 | DPP4 (0.64) | DPP4DPP7DPP8CYP3A4 | |
| SCHEMBL8483179 | 0.86 | DPP4 (0.67) | DPP4DPP7DPP8CYP3A4 | |
| SCHEMBL8474386 | 0.85 | DPP4 (0.65) | DPP4DPP7DPP8CYP3A4 | |
| SCHEMBL8474394 | 0.84 | DPP4 (0.61) | DPP4DPP7DPP8CYP3A4 | |
| SCHEMBL14006817 | 0.82 | DPP4 (0.71) | DPP4DPP7DPP8CYP3A4 | |
| SCHEMBL8491016 | 0.82 | DPP4 (0.61) | DPP4DPP7DPP8CYP3A4 | |
| SCHEMBL8490826 | 0.81 | DPP4 (0.60) | DPP4DPP7DPP8CYP3A4 | |
| SCHEMBL6460346 | 0.81 | DPP4 (0.70) | DPP4DPP7DPP8CYP3A4 | |
| SCHEMBL8377973 | 0.81 | DPP4 (0.94) | DPP4DPP7DPP8 | |
| SCHEMBL7858456 | 0.81 | DPP4 (0.94) | DPP4DPP7DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275086-A1 | Dpp-Iv Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2008-11-06 | — | — | US | disclosed |
| US-20080275086-A1 | Dpp-Iv Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2008-11-06 | — | — | US | disclosed |
| EP-1702916-A1 | DPP-IV inhibitors | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275086-A1 | Dpp-Iv Inhibitors | DPP4, DPP7, DPP3 | DPP4 1/4885DPP7 2/4885CYP2C9 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.